Curriculum Vitae. Dr. Amy Brenner is a board-certified obstetrician and gynecologist and board-certified in anti-aging and regenerative medicine, with more than 25 years of experience in women’s health, sexual medicine, and cosmetic gynecology.
Medical Licensure
- 2000–Present: State of Ohio Medical License
Hospital Affiliations
- Bethesda North Hospital, Cincinnati, Ohio
Certification
- American Board of Obstetricians and Gynecologists, 2003
Education
Miami University, Oxford, Ohio
August 1988 – May 1992
B.A. Zoology – Magna Cum Laude, Phi Beta Kappa
Medical College of Ohio, Toledo, Ohio
August 1992 – June 1996
Doctor of Medicine – Alpha Omega Alpha Honor Society
University of Louisville School of Medicine, Louisville, Kentucky
July 1996 – June 2000
Residency, Obstetrics and Gynecology
American Board of Anti-Aging and Regenerative Medicine / American Academy of Anti-Aging Medicine (A4M)
2016
Board Certified, Anti-Aging and Regenerative Medicine (ABAARM)
Alinsod Institute of Cosmetic Gynecology
May 2018
Positions
Spa Medicca
February 2025 – Present
- Physician
- Medical Director
- Board of Directors
- Responsible Person for Pharmacy Board Compliance
- Electronic Medical Record Optimization
Amy Brenner MD and Associates, LLC
July 2011 – February 2025
- Physician and Owner
- AAAASF Certified Office for IV Sedation
- Founded practice as sole physician with 4 employees; grew practice to over 50 employees prior to sale, including a second physician, 5 mid-level providers, 4 wellness coaches, and 3 skin care specialists
Obstetrics and Gynecology Associates
July 2000 – June 2011
- Physician, Owner/Partner
- Vice-President
- Executive Committee Member
- Medical Director of Nursing Call Center
- Medical Director of Office Procedures
- Medical Director of Osteoporosis
Media
- July 2021–Present: Creator and Host, “HealthiHer” Podcast
Expert Witness
- Expert Witness, Gynecology, Sexual Medicine, and Cosmetic Gynecology
Research Activities & Training
- 2000: Brenner A, Cook C, Fallat M, Siow Y. Mullerian Inhibiting Substances in Serum of Patients with Untreated Polycystic Ovarian Syndrome and Normal Women
- 2000: Brenner A, Cook C, Fallat M, Siow Y. Mullerian Inhibiting Substances in Serum of Normally Cycling Women at Various Stages of the Menstrual Cycle
- 2004: TASC — Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing
- 2005: Subinvestigator — Treatment of menstrually-related migraines — Phase II — complete
- 2013: NIH web-based training course (Protecting Human Research Participants)
- 2014: (Hologic) Evaluation of the safety of NovaSure in the presence of Essure following the Essure Confirmation Test (ECT) — complete
- 2015: (Bayer) Evaluation of the effectiveness of Essure post-NovaSure RF endometrial ablation procedure following the Essure Confirmation Test (ECT) — complete
- 2016: (Channel Medsystems) CLARITY: Pivotal Study — clinical study to evaluate the safety and effectiveness of the Cerene device to treat heavy menstrual bleeding — complete
- 2017: (Bayer) POET: An open-label, non-randomized, prospective observational cohort study to assess Post-procedural Outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure) or laparoscopic tubal sterilization — complete
- 2018: (Femasys) BLOC: Prospective multi-center office-based Bi-Lateral tubal occlusion trial for female permanent contraception (BLOC) device — complete
- 2018: (Bayer) ASTEROID 4: A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids — complete
- 2020: (Microcube) Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness (EASE clinical trial) — Principal Co-Investigator
Speakers Bureau (Former)
- Hologic/Cytyc Surgical, Inc.
- Bayer – Essure National Speaker
- Ethicon Women’s Healthcare
- CoolSculpting (formerly Zeltiq)
